NEFL and myeloid sarcoma: Various dependable biomarkers, such as MRI assessments, immunoglobulin G (IgG), oligoclonal bands (OCB), and neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF), have been recognized for tracking treatment responses in Multiple Sclerosis (MS) patients [1].